5-Amino-1MQ Side Effects: What Research Shows (2026)

What's Missing from the Dataset

A reviewer reading the published 5-amino-1MQ literature would note several limitations:

No human trial data. No Phase 1, Phase 2, or observational human study exists at the time of writing.

Limited duration. The reported preclinical dosing was 11 days; longer-term toxicity studies have not been published.

NNMT's role in cancer biology. NNMT is overexpressed in several cancers; the consequences of pharmacologic NNMT inhibition in users with subclinical malignancy are uncharacterized.

No published metabolic biomarker dataset for human use. Community sources describe self-monitored fasting glucose and weight changes; no validated biomarker tracking exists.

These are not safety findings — they are gaps in the safety dataset.

Self-Reported Community Adverse Events

Note on labeling: the events below come from r/peptides, r/PeptideTherapy, and forum sources for research-peptide oral or subcutaneous 5-amino-1MQ use. They are not from published trials.

Mild GI changes

The most consistent community feedback. Self-reported community sources describe transient appetite shifts and occasional loose stool in the first 1-2 weeks of use. The pattern fades by week 3 in nearly all reports.

Brief first-week fatigue

Community reports cluster around a 1-3 day fatigue window in the first week, sometimes attributed to metabolic shift. The pattern resolves by week 2 in most community reports.

Mild appetite suppression

Some users self-report mild appetite suppression as a target effect; others describe it as more pronounced than desired. The pattern is dose-dependent in community reports.

Sleep changes

Less consistently reported. Mixed pattern — some users describe deeper sleep, others describe early-morning waking. The mixed pattern suggests individual variation rather than a consistent drug effect.

Less Commonly Reported Events

These appear sparsely in community data.

Headache in the first 1-3 doses.

Lightheadedness at higher per-dose amounts.

Mild euphoria or "lightness" feeling during early use — community sources commonly attribute this to metabolic shift.

Dose-Response Patterns

Mouse studies tested 20 mg/kg subcutaneous, three injections per day. Community-reported research-peptide doses for oral or subcutaneous use cluster around 50-150 mg per day in adults. Self-reported community sources describe GI events scaling with per-dose amount and brief fatigue scaling with total daily dose.

No published research validates these dose-response relationships in humans.

Dose-Pause and Cycling Patterns

There is no published guideline for cycling 5-amino-1MQ. Community sources commonly describe cycles of 4-8 weeks on, 2-4 weeks off, citing the desire to assess off-cycle effects and the absence of long-term safety data as the rationale.

Permanent discontinuation in community reports is uncommon. Most-cited triggers: persistent GI symptoms, persistent fatigue, or the cycle simply ending.

Core Supplies for This Protocol

The three essentials for running any reconstituted injectable: cold storage, accurate syringes, and metabolic tracking.

Cooluli Classic 4L Mini Fridge

Compact thermoelectric mini-fridge with heat/cool toggle. The most-mentioned dedicated peptide-storage fridge in research community sources — fits ~20 vials and runs quietly.

BD Ultra-Fine 31G 0.3cc 5/16" Insulin Syringes (Box of 90)

0.3cc 31G syringes — each gradation marks 1 unit (vs 2 units on 1cc), making sub-50-unit peptide doses accurate. BD Ultra-Fine is the most widely-cited brand in peptide community sources.

CONTOUR NEXT GEN Glucose Meter All-In-One Kit

Ascensia's CONTOUR NEXT GEN — the most clinically-validated home glucose meter. Includes 20 test strips + lancing device. Tracks the blood-sugar response GLP-1 users care about, especially during dose escalation.

As an Amazon Associate, The Peptide Catalog earns from qualifying purchases.